SE9301667D0 - New use - Google Patents

New use

Info

Publication number
SE9301667D0
SE9301667D0 SE19939301667A SE9301667A SE9301667D0 SE 9301667 D0 SE9301667 D0 SE 9301667D0 SE 19939301667 A SE19939301667 A SE 19939301667A SE 9301667 A SE9301667 A SE 9301667A SE 9301667 D0 SE9301667 D0 SE 9301667D0
Authority
SE
Sweden
Prior art keywords
nmda
receptor
new use
glutamate
glutamate receptors
Prior art date
Application number
SE19939301667A
Other languages
English (en)
Swedish (sv)
Inventor
P *Bourguignon J
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE19939301667A priority Critical patent/SE9301667D0/xx
Publication of SE9301667D0 publication Critical patent/SE9301667D0/xx
Priority to NZ266559A priority patent/NZ266559A/xx
Priority to ES94916460T priority patent/ES2204916T3/es
Priority to AU68108/94A priority patent/AU685123B2/en
Priority to JP52470594A priority patent/JP3819932B2/ja
Priority to PCT/SE1994/000454 priority patent/WO1994026301A1/en
Priority to DK94916460T priority patent/DK0697886T3/da
Priority to CA002162924A priority patent/CA2162924C/en
Priority to EP94916460A priority patent/EP0697886B1/de
Priority to DE69433058T priority patent/DE69433058T2/de
Priority to AT94916460T priority patent/ATE247481T1/de
Priority to US08/549,798 priority patent/US5804550A/en
Priority to US10/087,011 priority patent/US20020115594A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE19939301667A 1993-05-14 1993-05-14 New use SE9301667D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE19939301667A SE9301667D0 (sv) 1993-05-14 1993-05-14 New use
AT94916460T ATE247481T1 (de) 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
JP52470594A JP3819932B2 (ja) 1993-05-14 1994-05-16 グルタミン酸塩およびｎｍｄａレセプターにおけるペプチド拮抗物質の使用方法
ES94916460T ES2204916T3 (es) 1993-05-14 1994-05-16 Nuevos antagonistas peptidos de los receptores de glutamato y nmda.
AU68108/94A AU685123B2 (en) 1993-05-14 1994-05-16 New peptide antagonists at glutamate and NMDA receptors
NZ266559A NZ266559A (en) 1993-05-14 1994-05-16 Peptide antagonists of cellular glutamate or NMDA receptors
PCT/SE1994/000454 WO1994026301A1 (en) 1993-05-14 1994-05-16 New peptide antagonists at glutamate and nmda receptors
DK94916460T DK0697886T3 (da) 1993-05-14 1994-05-16 Nye peptidantagonister for glutamat- og NMDA-receptorer
CA002162924A CA2162924C (en) 1993-05-14 1994-05-16 New peptide antagonists at glutamate and nmda receptors
EP94916460A EP0697886B1 (de) 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
DE69433058T DE69433058T2 (de) 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
US08/549,798 US5804550A (en) 1993-05-14 1995-11-09 Peptide antagonists at glutamate and NMDA receptors
US10/087,011 US20020115594A1 (en) 1993-05-14 2002-02-26 Peptide antagonists at glutamate and NMDA receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301667A SE9301667D0 (sv) 1993-05-14 1993-05-14 New use

Publications (1)

Publication Number Publication Date
SE9301667D0 true SE9301667D0 (sv) 1993-05-14

Family

ID=20389945

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939301667A SE9301667D0 (sv) 1993-05-14 1993-05-14 New use

Country Status (12)

Country Link
US (2) US5804550A (de)
EP (1) EP0697886B1 (de)
JP (1) JP3819932B2 (de)
AT (1) ATE247481T1 (de)
AU (1) AU685123B2 (de)
CA (1) CA2162924C (de)
DE (1) DE69433058T2 (de)
DK (1) DK0697886T3 (de)
ES (1) ES2204916T3 (de)
NZ (1) NZ266559A (de)
SE (1) SE9301667D0 (de)
WO (1) WO1994026301A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017204A1 (en) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
GB9611584D0 (en) * 1996-06-04 1996-08-07 Univ Edinburgh Neurotransmitters
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
WO2003086323A2 (en) * 2002-04-05 2003-10-23 Neuronz Limited Compositions and methods for immunomodulation
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
EP1529533A1 (de) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Behandlung von ischämischen Gehirnschäden mit Wachstumshormon-Sekretionsförderern
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596B1 (en) 2013-01-29 2023-12-06 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA201892657A1 (ru) 2016-05-19 2019-05-31 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
WO2018026792A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
US10961189B2 (en) 2016-08-01 2021-03-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017557A (en) * 1987-07-24 1991-05-21 Industria Farmaceutica Serono S.P.A. Treatment of infertility with somatotrophin releasing factor
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
CA2114251C (en) * 1991-08-01 2007-11-06 Peter Gluckman Igf-1 to improve the neural condition

Also Published As

Publication number Publication date
JPH08510214A (ja) 1996-10-29
ATE247481T1 (de) 2003-09-15
EP0697886A1 (de) 1996-02-28
EP0697886B1 (de) 2003-08-20
AU685123B2 (en) 1998-01-15
WO1994026301A1 (en) 1994-11-24
US5804550A (en) 1998-09-08
DE69433058T2 (de) 2004-06-03
CA2162924C (en) 2008-12-30
CA2162924A1 (en) 1994-11-24
DK0697886T3 (da) 2003-10-20
DE69433058D1 (de) 2003-09-25
JP3819932B2 (ja) 2006-09-13
US20020115594A1 (en) 2002-08-22
AU6810894A (en) 1994-12-12
NZ266559A (en) 2000-12-22
ES2204916T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
SE9301667D0 (sv) New use
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
NO951613L (no) Ikke-peptidyl tachykinin reseptorantagonister
DE59601122D1 (de) N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
ATE279517T1 (de) Il-17 receptor
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
EA199800052A1 (ru) Новые норпрегнаны для стимуляции гипоталамических эффектов
EA199800376A1 (ru) Антагонисты рецепторов возбудительной аминокислоты
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
DE68905845D1 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
DE69730515D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
SE9304236D0 (sv) New use
ATE240097T1 (de) Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten